PHILADELPHIA, Aug. 21, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of...
Related Questions
What is the potential impact of the class action lawsuit on Altimmune's near‑term stock price and volatility?
What precedent or similar biotech class action cases have occurred, and how did they influence market perception and valuation?
When is the deadline for investors to respond or opt‑out, and how might that affect trading volume?